Form 6-K TARO PHARMACEUTICAL INDU For: Nov 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Taro Pharma (TARO) Reports Q2 EPS of $3.11
November 4, 2015 7:16 AM ESTTaro Pharma (NYSE: TARO) reported Q2 EPS of $3.11, versus $3.35 reported last year. Revenue for the quarter came in at $212.1 million, versus $250.8 million reported last year.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
... More